SEC Form 4
Strata Critical Medical, Inc. (SRTA) insider trading
In the 12 months to Oct 26, 2026, 2 SRTA insiders reported open-market sales of $507.0K across 5 filings; 2 insiders bought $97.9K.
Latest filing · Last 12 months · Source: SEC EDGAR · How we count
- Open-market sales
- $507.0K
- 5 filings · 2 insiders
- Open-market purchases
- $97.9K
- 2 filings
- Pre-arranged sales (10b5-1)
- 2 of 5
- $382.3K of $507.0K sold (75%)
Who traded SRTA, and when
- Purchase
- Sale
- Sale, pre-arranged (10b5-1)
SRTA daily close from Oct 27, 2025 to Oct 26, 2026, between $4.03 and $6.47, last $4.80. 5 sale and 2 purchase filings by 4 insiders, marked at their filing dates. Amir Cohen, Chief Accounting Officer: sold $382.3K across 2 filings, first filed May 13, 2026, last May 26, 2026. Reginald Love, Director: sold $124.8K across 3 filings, first filed Nov 20, 2025, last Aug 13, 2026. William A. Heyburn, Co-CEO and CFO: bought $76.0K across 1 filing, first filed Dec 10, 2025, last Dec 10, 2025. Andrew Lauck, Director: bought $21.8K across 1 filing, first filed Dec 5, 2025, last Dec 5, 2025.
Largest mark · tap a row for others
Amir Cohen · Chief Accounting Officer
Sale $299,435
50,875 shares at $5.89 avg
Filed May 26, 2026 · traded May 21
Pre-arranged (10b5-1) · close on filing date $6.14
Amir Cohen · Chief Accounting Officer
Chief Accounting Officer
$382.3K soldReginald Love · Director
Director
$124.8K soldWilliam A. Heyburn · Co-CEO and CFO
Co-CEO and CFO
$76.0K boughtAndrew Lauck · Director
Director
$21.8K boughtOpen-market trades
7 filings in the last 12 months| Insider | Role | Sold | Bought | Filings | Pre-arranged (10b5-1) | Last filed |
|---|---|---|---|---|---|---|
| Amir Cohen | Chief Accounting Officer | $382.3K | — | 2 | 100% of sales | |
| Reginald Love | Director | $124.8K | — | 3 | — | |
| William A. Heyburn | Co-CEO and CFO | — | $76.0K | 1 | — | |
| Andrew Lauck | Director | — | $21.8K | 1 | — |
| Filed | Insider | Type | Shares | Avg price | Value | Held after | Source |
|---|---|---|---|---|---|---|---|
traded | Reginald Love Director | Sale | 5,091 | $5.75 | $29.3K | 146,481 | |
traded | Amir Cohen Chief Accounting Officer | SalePre-arranged (10b5-1) | 50,875 | $5.89 | $299.4K | 151,263 | |
traded | Amir Cohen Chief Accounting Officer | SalePre-arranged (10b5-1) | 14,306 | $5.79 | $82.8K | 202,138 | |
traded | William A. Heyburn Co-CEO and CFO | Purchase | 17,000 | $4.47 | $76.0K | 1,403,436 | |
traded | Andrew Lauck Director | Purchase | 5,000 | $4.37 | $21.8K | 135,642 | |
traded | Reginald Love Director | Sale | 11,000 | $4.37 | $48.1K | 113,897 | |
traded | Reginald Love Director | Sale | 11,000 | $4.31 | $47.4K | 124,897 |
GET /stocks/filings/vX/form-4?tickers=SRTA&filing_date.gte=2025-10-26&sort=filing_date.desc&limit=500{
"status": "OK",
"results": [
{
"tickers": [
"SRTA"
],
"issuer_cik": "0001779128",
"owner_cik": "0001749370",
"accession_number": "0001628280-26-056841",
"form_type": "4",
"filing_date": "2026-08-13",
"period_of_report": "2026-08-10",
"issuer_name": "Strata Critical Medical, Inc.",
"issuer_trading_symbol": "SRTA",
"owner_name": "Love Reginald",
"is_director": true,
"is_officer": false,
"is_ten_percent_owner": false,
"is_other": false,
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Class A common stock, $0.0001 par value per share",
"transaction_timeliness": "O",
"aff_10b5_one": false,
"transaction_date": "2026-08-10",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 5091,
"transaction_price_per_share": 5.75,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 146481,
"transaction_value": 29273.25,
"not_subject_to_section_16": false,
"direct_or_indirect": "D"
},
{
"tickers": [
"SRTA"
],
"issuer_cik": "0001779128",
"owner_cik": "0001861140",
"accession_number": "0001628280-26-038171",
"form_type": "4",
"filing_date": "2026-05-26",
"period_of_report": "2026-05-21",
"issuer_name": "Strata Critical Medical, Inc.",
"issuer_trading_symbol": "SRTA",
"owner_name": "Cohen Amir",
"is_director": false,
"is_officer": true,
"is_ten_percent_owner": false,
"is_other": false,
"officer_title": "Chief Accounting Officer",
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Class A common stock, $0.0001 par value per share",
"transaction_timeliness": "O",
"aff_10b5_one": true,
"transaction_date": "2026-05-22",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 40575,
"transaction_price_per_share": 5.91,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 151263,
"transaction_value": 239798.25,
"not_subject_to_section_16": false,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F1",
"description": "This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 10, 2025."
},
{
"id": "F2",
"description": "The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.81 to $6.02, inclusive. The reporting person undertakes to\nprovide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price\nwithin the ranges set forth in this footnote to this Form 4."
}
]
}
]
}
// trimmed to 2 resultsThe response includes every Form 4 record; this page keeps open-market purchases and sales on common stock and removes duplicate joint-filer rows.
Other insider activity (not market trades) · 66 records
- Option exercises2 records
- Tax withholding32 records
- Tax withholding (sold to cover)4 records
- Grants and awards28 records
Reported on Form 4 but not purchases or sales in the market, so not counted in the totals above.
How to read this page
- Open-market purchase or sale
- A buy or sell of the company's stock at market price. Grants, option exercises, shares withheld for tax, gifts and employee stock plan purchases are listed separately and not counted.
- Pre-arranged (10b5-1)
- The insider marked the filing as made under a trading plan set up in advance (SEC Rule 10b5-1). The mark covers the whole filing, and an unmarked filing may still be under a plan.
- Filing date
- Insiders have two business days to report a trade. Totals and the chart use the filing date, when the trade became public.
Frequently asked questions
Has Strata Critical Medical, Inc.'s CEO sold stock?
No. Melissa M. Tomkiel and William A. Heyburn and Louis R. Verdetto and Scott M. Wunsch (CEOs) made no open-market sales filed as CEO in the last 12 months.
How current is SRTA’s insider data?
These are SRTA Form 4 filings from the last year, refreshed daily. The Massive Form 4 API has the full, continuously updated record.
What counts as an open-market buy or sell?
Only purchases and sales at the market price. Option exercises, grants, gifts, and shares withheld for taxes are reported on Form 4 but are left out of the buy and sell totals.
Build with AI
Track SRTA insider trades with your agent
This page joins two Massive endpoints: Form 4 filings and daily prices. Ask an agent to watch for new filings:
Using the Massive API (massive.com/docs/llms.txt), check Form 4 filings for SRTA every day with transaction_code=P and tell me when an insider files an open-market purchase, with their role, shares, price and the filing link.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.